SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion.

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Due Diligence who wrote (29188)2/18/2000 7:12:00 PM
From: Bidder  Read Replies (1) of 150070
 
FSMEP! 5 bagger next week!!
NEWS...The Wall Street Transcript Publishes Healthcare Facilities Analyst Interview
PR Newswire - February 18, 2000 08:46

NEW YORK, Feb. 18 /PRNewswire/ -- Seven leading analysts and CEOs or top management from sixty Healthcare firms examine the Healthcare sector in the latest issue of The Wall Street Transcript (212/952-7433) or twst.com

In a vital review of this sector for investors and industry professionals, this valuable 223-page Special Issue features:

1) Healthcare Facilities - In an in-depth Analyst Interview (7,500 words) Howard Capek, Executive Director with Warburg Dillon Read, and Matt Ripperger, Director with Warburg Dillon Read's Healthcare research group, examine the business models of long term care companies, new developments, the outlook for the sector, and offer specific stock recommendations.

Capek discusses the components of the sector which include "Acute care hospitals, psychiatric hospitals, and rehabilitation, all of which include inpatient and outpatient long-term care or skilled nursing; senior living, which as we define it, includes assisted and independent living; and finally, home healthcare."

Capek rates the publicly traded players in the kidney dialysis space: "Fresenius Medical Care AG (NYSE: FMS), which I have rated Buy, is a global, vertically integrated company that treats roughly 25% of the US population and 8% of the worldwide population. They also manufacture a kidney dialysis product and have, again, roughly 20% market share worldwide."

FMS and FSMEP are the same company, this is simply the prefered class D Stock.

Next week should be very interesting!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext